Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Clearstead Trust LLC

Clearstead Trust LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 31.1% during the fourth quarter, Holdings Channel reports. The fund owned 195 shares of the life sciences company’s stock after selling 88 shares during the quarter. Clearstead Trust LLC’s holdings in Illumina were worth $27,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Illumina by 15.0% during the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock worth $2,466,614,000 after purchasing an additional 2,336,935 shares during the period. Barclays PLC grew its holdings in Illumina by 120.0% in the 3rd quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock valued at $242,758,000 after buying an additional 964,709 shares during the period. abrdn plc increased its stake in shares of Illumina by 764.9% during the 4th quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after acquiring an additional 299,827 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Illumina by 245.7% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company’s stock worth $57,366,000 after acquiring an additional 296,990 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of Illumina during the 3rd quarter worth about $29,558,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In related news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research analyst reports. Robert W. Baird upped their price target on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research report on Friday. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Stephens restated an “overweight” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. HSBC cut Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus target price of $165.10.

Illumina Stock Down 4.9 %

ILMN traded down $6.06 during trading on Friday, hitting $117.93. The company had a trading volume of 2,987,105 shares, compared to its average volume of 1,375,095. The business has a 50-day moving average of $130.03 and a 200-day moving average of $127.00. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $213.91. The company has a market cap of $18.78 billion, a PE ratio of -14.47 and a beta of 1.20. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Illumina had a positive return on equity of 2.28% and a negative net margin of 28.71%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 EPS. As a group, analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.